Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 338-343

  Suzuki, Shiro ^a   Shibata, Kiyosumi ^a   Kikkawa, Fumitaka ^a   Nakatsura, Tetsuya ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

Clinical response; Glypican 3; Ovarian clear cell carcinoma; Peptide vaccine; Refractory disease

Indexed keywords

CA 125 ANTIGEN; CA 72-4 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN GLYPICAN 3; CISPLATIN; DOCETAXEL; GEMCITABINE; HLA A ANTIGEN; IRINOTECAN; NEDAPLATIN; PACLITAXEL; PEPTIDE VACCINE; TUMOR MARKER; UNCLASSIFIED DRUG; FREUND ADJUVANT; GLYPICAN; GPC3 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG RESPONSE; FEMALE; FEVER; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PATIENT HISTORY OF SURGERY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; CARCINOMA; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PROCEDURES; RECURRENT DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CARCINOMA; FEMALE; FREUND'S ADJUVANT; GLYPICANS; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; OVARIAN NEOPLASMS; RECURRENCE; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84896928987     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27217     Document Type: Article

References (17)

1. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32:342-9; PMID:2920955; http://dx.doi. org/10.1016/0090-8258(89)90637-9 (Pubitemid 19074926)
2. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88:2584-9; PMID:10861437; http://dx.doi. org/10.1002/1097-0142(20000601)88:112584::AIDCNCR223.0.CO;2-5 (Pubitemid 30331967)
3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109:370-6; PMID:18395777; http://dx.doi.org/10.1016/j.ygyno.2008.02.006
4. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007; 105:404-8; PMID:17292461; http://dx.doi.org/10.1016/ j. ygyno.2006.12.024 (Pubitemid 46590333)
5. Takano M, Goto T, Kato M, Sasaki N, Miyamoto M, Furuya K. Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. Int J Clin Oncol 2013; 18:556-7; PMID:22552358; http://dx.doi.org/10.1007/ s10147-012-0404-x
6. Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer 2012; 22:801- 6; PMID:22617480; http://dx.doi.org/10.1097/ IGC.0b013e3182540145
7. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx.doi. org/10.1016/S0006-291X(03) 00908-2 (Pubitemid 36629398)
8. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10:6612-21; PMID:15475451; http://dx.doi.org/10. 1158/1078- 0432.CCR-04-0348 (Pubitemid 39346558)
9. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000; 89:418-22; PMID:11008203; http://dx.doi.org/10.1002/ 1097- 0215(20000920)89:53.0.CO; 2-I
10. Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001; 23:496-9; PMID:11878776; http://dx.doi. org/10.1097/00043426-200111000-00006 (Pubitemid 33123699)
11. Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008; 21:817-25; PMID:18469798; http://dx.doi.org/10. 1038/modpathol.2008.37 (Pubitemid 351896655)
12. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22:824-32; PMID:19329941
13. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, et al. Identification of HLAA2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689-97; PMID:16675560; http://dx.doi. org/10.1158/1078-0432.CCR-05-2267
14. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11- 3044
15. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, Nijman HW. Antigenspecific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 2010; 20:CD007287; PMID:20091627
16. Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:622-9; PMID:21205085; http://dx.doi. org/10.1111/j.1349-7006.2011.02003.x
17. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi. org/10.1200/JCO.2012.41.6750